Wetin mek i at fɔ trit sɔm kayn bɔdi kansa? Lɛ wi tɔk bɔt dɛn nyu tritmɛnt ya (Hard-to-Treat Breast Cancer) .

We dɛn no se pɔsin gɛt bɔdi kansa, i kin rili fil bad ɛn fred. Dat na nɔmal tin. Bɔt wit di advans mɛdikal sayɛns tide, dɛn kin ebul fɔ kɔntrol bɔku pan di kayn bɔdi kansa dɛn ɛn mɛn dɛn. Bɔt sɔm kayn kansa de we at fɔ trit smɔl pas ɔda wan dɛn. Dɛn kɔl dɛn tin ya "brɔst kansa we at fɔ trit." Di wan dɛn we de stɔdi bɔt mɛrɛsin gɛt bɔku op fɔ dis, bikɔs dɛn de mek nyu tritmɛnt dɛn ɛvride. Lɛ wi tɔk bɔt dis tide.

Wetin mek i nɔ izi fɔ trit sɔm kansa dɛn we de na di bɔdi?

Fɔ tɔk am simpul wan, di tritmɛnt dɛn we kin wok fayn pas ɔl fɔ gɛt bɔdi kansa, na fɔ kɔntrol aw di kansa sɛl dɛn kin gro. Tink bɔt dis we: if kansa sɛl tan lɛk domɔt, sɔm ɔmon ɛn prɔtin dɛn tan lɛk di ki dɛn we de opin da domɔt de. di tritmεnt dεm de wok bay we dεn de blכk di do dεm (rεsεpכta dεm) so dat dεn ki dεm ya nכ go wok. di brεst kεnsar dεn sheb am to tri men tכp dεm bay di kayn ‘do dεm’.

Naw lɛ wi si wetin na dɛn tri kayn dɛn ya.

Bitwin 10% ɛn 20% pan ɔl di wan dɛn we gɛt bɔdi kansa gɛt disNa wan kayn bɔdi kansa we dɛn kɔl tripl-negative breast cancer (TNBC). Ɔmon tritmɛnt dɛm wae dɛn kin yuse fayn fayn wan fɔ ɔda kayn kansa nɔr kin woke fɔ dis kayn kansa, bikɔs i nɔr gɛt ɔmon risepta. Dɔn bak, drɔgs dɛn we de tɔch HER2 nɔ de ɛp.

Apat frɔm dat, TNBC kansa kin agresiv pas ɔda kayn kansa dɛn. Dis min se di kansa kin dɔn pas ɔda pat dɛn na di bɔdi bay di tɛm we dɛn no se i gɛt am. I kin biev difrɛn we bak pan ɛnibɔdi, ɛn i kin chenj as tɛm de go fɔ mek i nɔ ebul fɔ tek sɔm mɛrɛsin dɛn.

Aw di chenj dɛn we de apin na di jɛnɛtiks kin afɛkt dis?

Wan pan di bɛst we fɔ no bɔt kansa lɛk TNBC kwik kwik wan na fɔ no di wan dɛn we gɛt ay risk. Fɔ du dis, di wan dɛn we de stɔdi bɔt dis de stɔdi bɔt di chenj dɛn we kin apin na di jɛnɛtiks (muteshɔn) we kin pas frɔm jɛnɛreshɔn dɛn ɛn we gɛt fɔ du wit bɔdi kansa.

• BRCA1 ( brɔst kansa jin 1) .
• BRCA2 (Brest Kansa Jin 2) .

If yu gɛt wan muteshon na wan pan dɛn tu jin ya, yu go gɛt bɔku kansa na yu bɔdi ɛn ovarian. If yu gɛt dis muteshon, yu kin gɛt kansa bak we yu yɔŋ.

כl di brεst kεnsar dεm we gεt BRCA1 jin mכtεshכn na tripl-nεgεtiv . So, if yu ɔndastand dis jin, i go ɛp fɔ fɛn bɛtɛ we fɔ trit TNBC.

Wetin yu nid fɔ no bɔt mɛtastas brɔst kansa?

Wan ɔda kayn kansa we at fɔ mɛn na bɔdi kansa we dɔn skata na di say dɛn we de fa fawe na di bɔdi. Dɛn kɔl dis mɛtastas brɔst kansa . I kin pas to ɔda pat dɛn na di bɔdi lɛk di bon dɛn, di bren, di liva, ɔ di lɔng dɛn. Sɔntɛnde, dɛn kin no di kansa we i dɔn skata dis we. Bɔt bɔku tɛm, di kansa kin kam bak ɛn prɛd afta dɛn dɔn trit am fɔs, sɔm tɛm dɛn kin afta sɔm ia.

Yu brɔst kansaIf di kansa dɔn skata na say dɛn we de fa, di men gol fɔ tritmɛnt na fɔ kɔntrol di kansa. Sεstεmik tεrapi na di mכst kכmכn tritmεnt fכ dis. Yu dɔktɔ go disayd fɔ yu tritmɛnt bay di sayn dɛm we yu gɛt, di tritmɛnt dɛm we yu bin dɔn gɛt trade, usay di kansa dɔn skata, ɛn di kayn kansa sɛl dɛm.

Wetin na di las tritmɛnt fɔ dis?

Di tritmɛnt fɔ TNBC, mɛtastas ɛn rikɔrɛnt brɔst kansa, dɔn impɔtant bad bad wan insay di las ia. Kimotɛrapi na di men tritmɛnt fɔ dis. Dɔktɔ dɛn naw de gi am togɛda wit ɔda mɛrɛsin dɛn.

Na sɔm ɔda nyu tritmɛnt dɛn ya:

PARP inhibito dɛn

dis na wan kayn dכg we de pwεl di DNA fכ di kεnsar sεl dεm na pipul dεm we gεt BRCA jin mכtεshכn εn HER2-nεgεtiv εn mεtastas kεnsar. εgzampl dεm na `olaparib (Lynparza)` εn `talazoparib (Talzenna).` dεn ya dεn sho gud risכlt bak fכ di εli stej TNBC.

Imyunotɛrapi

Dɛn tritmɛnt ya kin mek di bɔdi in yon imyun sistɛm pwɛl fɔ pwɛl di kansa sɛl dɛn. Pembrolizumab (Keytruda) na wan pan dɛn kayn mɛrɛsin dɛn de. Bɔku tɛm, dɛn kin gi dɛn togɛda wit kemotɛrapi.

Antibodi-drɔg kɔnjɔgɛt (ADC) dɛn .

Dis na teknɔlɔji we rili intrestin. Tink bɔt am lɛk GPS sistem we de gayd wan drɔg fɔ rich usay i want fɔ go. Di antibodi dɛm we de insay dɛn drɔgs ya kin fɛn kansa sɛl dɛm, atak dɛn, ɛn pwɛl di kansa sɛl dɛm wit di drɔg we atak, ɛn nɔ kin ambɔg di wɛlbɔdi sɛl dɛm. `Sacituzumab govitecan (Trodelvy)` na ADC drɔg we dɛn dɔn gri fɔ fɔ advans TNBC.

Ad-ɔn tritmɛnt dɛn

Bɔku nyu mɛrɛsin dɛn de we dɛn kin gi togɛda wit ɔmon tɛrapi fɔ ɔmon riseptɔ (HR)-pɔzitiv kansa. Abemaciclib (Verzenio) na wan pan dɛn kayn mɛrɛsin dɛn de.

Wetin na di tin dɛn we wi go gɛt tumara bambay pan dis?

Risach pipul dɛm de wok ɔltɛm fɔ mek dɛn gɛt mɔ tritmɛnt opshɔn fɔ dɛn kansa ya, inklud fɔ fɛn nyu imyunotɛrapi kɔmpawnd ɛn fɔ no mak dɛm we go ebul fɔ no wetin go apin to di tritmɛnt.

Dɛn de chɛk bak if di mɛrɛsin dɛn we dɛn dɔn gri fɔ fɔ ɔda sik dɛn go fayn fɔ TNBC. Dɛn de invɛstigat bak aw fɔ yuz drɔgs lɛk PARP inhibitors mɔ brayt wan. Sɔm stɔdi dɛn de tray bak fɔ yuz nanoparticles we go bɛnifit di bɔdi fɔ kil di kansa sɛl dɛn we nɔ de tek drɔgs.

So, pan ɔl we fɔ liv wit dis kayn kansa kin tranga, op de fɔ gɛt nyu tritmɛnt. Di tin we impɔtant pas ɔl na fɔ tɔk to yu dɔktɔ ɔltɛm ɛn disayd bɔt di tritmɛnt plan we go fayn fɔ yu.